BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kearns GL. Beyond biomarkers: an opportunity to address the 'pharmacodynamic gap' in pediatric drug development. Biomark Med. 2010;4:783-786. [PMID: 21133695 DOI: 10.2217/bmm.10.106] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Hartman SJF, Swaving JGE, van Beek SW, van Groen BD, de Hoop M, van der Zanden TM, Ter Heine R, de Wildt SN. A New Framework to Implement Model-Informed Dosing in Clinical Guidelines: Piperacillin and Amikacin as Proof of Concept. Front Pharmacol 2020;11:592204. [PMID: 33390970 DOI: 10.3389/fphar.2020.592204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Smits A, De Cock RF, Cossey V, Knibbe CA, Allegaert K. Is indirect hyperbilirubinemia a useful biomarker of reduced propofol clearance in neonates? Biomark Med 2012;6:283-9. [PMID: 22731901 DOI: 10.2217/bmm.12.25] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
3 Kelly LE, Sinha Y, Barker CIS, Standing JF, Offringa M. Useful pharmacodynamic endpoints in children: selection, measurement, and next steps. Pediatr Res 2018;83:1095-103. [PMID: 29667952 DOI: 10.1038/pr.2018.38] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
4 Allegaert K. Clinical pharmacological studies in children: From exploratory towards confirmation driven methodology. World J Clin Pediatr. 2012;1:3-7. [PMID: 25254160 DOI: 10.5409/wjcp.v1.i2.3] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Ashish N, Bamman MM, Cerny FJ, Cooper DM, D'Hemecourt P, Eisenmann JC, Ericson D, Fahey J, Falk B, Gabriel D, Kahn MG, Kemper HC, Leu SY, Liem RI, McMurray R, Nixon PA, Olin JT, Pianosi PT, Purucker M, Radom-Aizik S, Taylor A. The clinical translation gap in child health exercise research: a call for disruptive innovation. Clin Transl Sci 2015;8:67-76. [PMID: 25109386 DOI: 10.1111/cts.12194] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
6 Becker ML. Optimization of Pediatric Rheumatology Therapeutics. Clin Pharmacol Ther 2012;91:597-606. [DOI: 10.1038/clpt.2011.293] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
7 Funk RS, Becker ML. Disease modifying anti-rheumatic drugs in juvenile idiopathic arthritis: striving for individualized therapy. Expert Review of Precision Medicine and Drug Development 2016;1:53-68. [DOI: 10.1080/23808993.2016.1133234] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
8 van den Anker J, Allegaert K. Clinical pharmacology in neonates and young infants: the benefit of a population-tailored approach. Expert Rev Clin Pharmacol. 2012;5:5-8. [PMID: 22142152 DOI: 10.1586/ecp.11.65] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
9 Wagner JA. Innovations driving biomarker evaluation and use. Biomark Med 2010;4:779-81. [PMID: 21133694 DOI: 10.2217/bmm.10.114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]